EX-99.3 4 factsheet.htm FACT SHEET- WORD VERSION




Corporate Fact Sheet

May 2016

STOCK INFORMATION (as of May 9, 2016)

Ticker:      CEMI
Exchange:    Nasdaq
Share Price:    $7.35/share
Market Cap:    $70.93 Million


CORPORATE HIGHLIGHTS


•  Global Provider of High Quality POC  Infectious Disease Assays
     •  Sales in 40+ countries, including U.S.

·
Consistent Revenue Growth (5 Year 8% CAGR)


•  Patented DPP® (Dual Path Platform)  Technology
     •  DPP® HIV 1/2 Assay for Blood/Oral Fluid
     •  Multiple products sold into Latin America and U.S.


·
Future Pipeline of DPP® POC Assays   (internal development)
     • DPP® HIV-Syphilis Combination Assay (U.S.)
     • DPP®Malaria Assay
·
DPP® Chikungunya Assay

•  Ongoing Collaborations/Development Projects:
•  DPP® Malaria Assay (Oral Fluid/Saliva)
·
    DPP® Zika Assay
·
    DPP® Dengue Assay
·
   DPP® Zika/Dengue/Chikungunya Assay
·
    DPP® Fever Panel Assay
·
   DPP® Malaria/Ebola Assay
·
   DPP® Flu Immunostatus
·
   DPP® Traumatic Brain Injury
·
   DPP® Cancer (specific form)
·
   DPP® Micro Reader



COMPANY SNAPSHOT


Chembio Diagnostics, Inc. (NASDAQ: CEMI) develops, manufactures, licenses and markets rapid diagnostic assays in the growing $8.0 billion point-of-care (POC) testing market.  In addition to its branded and proprietary HIV assays, which it sells in the U.S. and internationally, the Company has several ongoing collaborations for the development of diagnostic assays for Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg, flu immunostatus, brain injury and a specific form of cancer.

Dual Path Platform (DPP®) is Chembio's patented POC technology, which offers significant advantages over lateral-flow technologies, including enhanced sensitivity and the ability to conduct multiple tests from a single sample (multiplexing).  DPP® continues to  provide Chembio with a growing pipeline of business opportunities for the development and manufacture of new products.

CHEMBIO'S LEAD PRODUCTS

DPP® HIV-Syphilis Assay *available in selected markets
o
Rapid, multiplex detection of HIV 1, HIV 2 and syphilis using a single sample
DPP® HIV 1/2 Assay
o
Rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices
HIV 1/2 STAT-PAK® Assay
o
Single-use, rapid, visual detection of HIV 1 and HIV 2 antibodies
SURE CHECK® HIV 1/2 Assay
o
Self-contained, single-use collection & testing device
(See graphics)

PAGE 2
CHEMBIO'S DPP® DUAL PATH PLATFORM
o
Patented technology
o
Allows improved sensitivity and specificity compared to lateral flow technology
o
Enables multiple test results via a single blood sample (e.g., HIV-Syphilis Combo Assay)
o
Offers application within infectious disease and potential for a number of other indications
(See graphics)
Sexually Transmitted Diseases
HIV
o
35 million people living with HIV/AIDS worldwide (2013)
o
More than 1.1 million people in the U.S. are living with HIV infection, and almost 1 in 8 (15.8%) are unaware of their infection
SYPHILIS
o
Approx. 12 million people globally become ill with syphilis annually
o
From 2005-2013, syphilis cases in the U.S. nearly doubled, from 8,724 to 16,663
Fever Diseases

Malaria
·
Approximately 214 million infections and 438,000 deaths annually (2015)

Dengue Fever
·
Approximately 400 million infections annually with 40% of the world population at risk (2015)

Ebola
·
Approximately 28,000 infections and 11,000 deaths in 2014 – 2015

Zika
·
In February 2016,  WHO declared the Zika virus a "public health emergency of international concern," as the virus spread to more than 40 countries.

DPP PIPELINE & COLLABOTATORS
Chembio Internal Development:
o
DPP® HIV-Syphilis Assay (testing in U.S. market)
o
DPP® Malaria Assay
o
DPP® Chikungunya Assay
Development Collaborations
•    DPP® Malaria Oral Fluid/Saliva- The Bill & Melinda Gates Foundation
·
DPP® Zika- The Paul G. Allen Family Foundation
·
DPP® Dengue Fever – Undisclosed collaborator
•    DPP® Zika/Dengue/Chikungunya- The Paul G. Allen Family Foundation
•    DPP® Fever Panel – The Paul G. Allen Ebola Program
·
DPP® Malaria/Ebola & Dpp® Ebola Assays- CDC
·
DPP® Flu Immunostatus – CDC Contractor
•    DPP® Traumatic Brain Injury – Perseus Science Group LLC
•    DPP® Cancer (a specific form) – Undisclosed collaborator


Tech transfer and Distribution
o
DPP® technology for Geenius™ HIV 1/2 Confirmatory Assay – Bio Rad
o
DPP® product distribution in Brazil- Oswaldo Cruz Foundation
o
DPP® co-branding and distribution in Brazil- Labtest, Diagnostica SA
o
DPP® tech transfer, manufacture and distribution in Malaysia- RVR
o
DPP® Micro Reader

CORPORATE OFFICERS
John J. Sperzel III, Chief Executive Officer
Richard Larkin, CPA, Chief Financial Officer
Sharon Klugewicz, M.S., Chief Operating Officer
Javan Esfandiari, M.S., Chief Science & Technology Officer


 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Vida Strategic Partners
Susan Norcott
 Medford, NY 11763
Stephanie C. Diaz
 631-924-1135 x125
 Ph. 631-924-1135
(415) 675-7401
 snorcott@chembio.com
 Fax 631-924-2065
sdiaz@vidasp.com
 
 www.chembio.com